Endometriosis-Pipeline Review, H1 2016

Endometriosis-Pipeline Review, H1 2016


  • Products Id :- GMDHC7713IDB
  • |
  • Pages: 131
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Endometriosis-Pipeline Review, H1 2016', provides an overview of the Endometriosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Endometriosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Endometriosis

The report reviews pipeline therapeutics for Endometriosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Endometriosis therapeutics and enlists all their major and minor projects

The report assesses Endometriosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Endometriosis

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Endometriosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Endometriosis Overview 11

Therapeutics Development 12

Pipeline Products for Endometriosis-Overview 12

Pipeline Products for Endometriosis-Comparative Analysis 13

Endometriosis-Therapeutics under Development by Companies 14

Endometriosis-Therapeutics under Investigation by Universities/Institutes 16

Endometriosis-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Endometriosis-Products under Development by Companies 21

Endometriosis-Products under Investigation by Universities/Institutes 23

Endometriosis-Companies Involved in Therapeutics Development 24

AbbVie Inc. 24

Addex Therapeutics Ltd 25

APAvadis Biotechnologies Srl 26

Astellas Pharma Inc. 27

Bayer AG 28

Dongkook Pharmaceutical Co., Ltd. 29

ElexoPharm GmbH 30

EndoCeutics, Inc. 31

Euroscreen S.A. 32

Evotec AG 33

Forendo Pharma Limited 34

GlaxoSmithKline Plc 35

Kissei Pharmaceutical Co., Ltd. 36

Lipicard Technologies Limited 37

Nippon Shinyaku Co., Ltd. 38

Orphagen Pharmaceuticals, Inc. 39

Philogen S.p.A. 40

Repros Therapeutics Inc. 41

SK Chemicals Co., Ltd. 42

Takeda Pharmaceutical Company Limited 43

ValiRx Plc 44

Endometriosis-Therapeutics Assessment 45

Assessment by Monotherapy Products 45

Assessment by Combination Products 46

Assessment by Target 47

Assessment by Mechanism of Action 50

Assessment by Route of Administration 52

Assessment by Molecule Type 54

Drug Profiles 56

(anastrozole + levonorgestrel)-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

acolbifene hydrochloride + GnRH Agonist + prasterone-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

ASP-1707-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

BAY-1128688-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

bentamapimod-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Drug to Inhibit C-Jun for Endometriosis-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Drugs for Endometriosis-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Drugs for Endometriosis and Uterine Fibroids-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

elagolix sodium-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

epelsiban besylate-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

ESN-364-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

EVE-104-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

FP-5677-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

goserelin biosimilar-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

KLH-2109-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

LT-6121-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

MIA-602-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

NS-580-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

Peptides for Hepatic Tumor and Endometriosis-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Peptides to Inhibit Aminopeptidase A for Hepatic (Liver) Tumor and Endometriosis-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

PGL-2001-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

relugolix-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

SKI-2670-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Small Molecule to Antagonize FSH Receptor for Women's Health-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

SR-16234-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

telapristone acetate-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

Tetravil-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

triptorelin biosimilar-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

VAL-201-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

vilaprisan-Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

VPE-001-Drug Profile 103

Product Description 103

Mechanism of Action 103

R&D Progress 103

VPEA-004-Drug Profile 104

Product Description 104

Mechanism of Action 104

R&D Progress 104

Endometriosis-Recent Pipeline Updates 105

Endometriosis-Dormant Projects 120

Endometriosis-Discontinued Products 122

Endometriosis-Product Development Milestones 123

Featured News & Press Releases 123

Feb 10, 2016: AbbVie Announces Positive Top-Line Results From Second Phase 3 Study Investigating Elagolix in Patients with Endometriosis 123

Dec 21, 2015: Repros Updates Proellex Program 124

Mar 24, 2015: Bayer to present new preclinical, early clinical and epidemiological data on BAY 98-7196 at 62nd Annual Scientific Meeting, March 25-28, 2015, in San Francisco, CA 124

Mar 24, 2015: Bayer to present new preclinical, early clinical and epidemiological data on Vilaprisan at 62nd Annual Scientific Meeting, March 25-28, 2015, in San Francisco, CA 125

Feb 26, 2015: New Endometriosis Patent Grant for ValiRx 126

Jan 15, 2015: Clinical Trial and Development Update on VAL201 for oncology indications 127

Jan 08, 2015: Abbvie Announces Positive Top-Line Results From Phase 3 Study Of Investigational Medicine Elagolix In Patients With Endometriosis 127

Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting 128

Apr 01, 2014: ValiRx Provides Updated On Anti-cancer Therapeutic VAL201 128

Mar 13, 2014: New drug candidate showed efficacy in human endometriosis samples 129

Appendix 130

Methodology 130

Coverage 130

Secondary Research 130

Primary Research 130

Expert Panel Validation 130

Contact Us 130

Disclaimer 131

List of Figures

Number of Products under Development for Endometriosis, H1 2016 12

Number of Products under Development for Endometriosis-Comparative Analysis, H1 2016 13

Number of Products under Development by Companies, H1 2016 14

Number of Products under Investigation by Universities/Institutes, H1 2016 16

Comparative Analysis by Clinical Stage Development, H1 2016 18

Comparative Analysis by Early Stage Products, H1 2016 19

Assessment by Monotherapy Products, H1 2016 45

Assessment by Combination Products, H1 2016 46

Number of Products by Top 10 Targets, H1 2016 47

Number of Products by Stage and Top 10 Targets, H1 2016 47

Number of Products by Top 10 Mechanism of Actions, H1 2016 50

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 50

Number of Products by Routes of Administration, H1 2016 52

Number of Products by Stage and Routes of Administration, H1 2016 52

Number of Products by Molecule Types, H1 2016 54

Number of Products by Stage and Molecule Types, H1 2016 54

List of Tables

Number of Products under Development for Endometriosis, H1 2016 12

Number of Products under Development for Endometriosis-Comparative Analysis, H1 2016 13

Number of Products under Development by Companies, H1 2016 15

Number of Products under Investigation by Universities/Institutes, H1 2016 16

Comparative Analysis by Late Stage Development, H1 2016 17

Comparative Analysis by Clinical Stage Development, H1 2016 18

Comparative Analysis by Early Stage Development, H1 2016 19

Comparative Analysis by Unknown Stage Development, H1 2016 20

Products under Development by Companies, H1 2016 21

Products under Development by Companies, H1 2016 (Contd..1) 22

Products under Investigation by Universities/Institutes, H1 2016 23

Endometriosis-Pipeline by AbbVie Inc., H1 2016 24

Endometriosis-Pipeline by Addex Therapeutics Ltd, H1 2016 25

Endometriosis-Pipeline by APAvadis Biotechnologies Srl, H1 2016 26

Endometriosis-Pipeline by Astellas Pharma Inc., H1 2016 27

Endometriosis-Pipeline by Bayer AG, H1 2016 28

Endometriosis-Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2016 29

Endometriosis-Pipeline by ElexoPharm GmbH, H1 2016 30

Endometriosis-Pipeline by EndoCeutics, Inc., H1 2016 31

Endometriosis-Pipeline by Euroscreen S.A., H1 2016 32

Endometriosis-Pipeline by Evotec AG, H1 2016 33

Endometriosis-Pipeline by Forendo Pharma Limited, H1 2016 34

Endometriosis-Pipeline by GlaxoSmithKline Plc, H1 2016 35

Endometriosis-Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016 36

Endometriosis-Pipeline by Lipicard Technologies Limited, H1 2016 37

Endometriosis-Pipeline by Nippon Shinyaku Co., Ltd., H1 2016 38

Endometriosis-Pipeline by Orphagen Pharmaceuticals, Inc., H1 2016 39

Endometriosis-Pipeline by Philogen S.p.A., H1 2016 40

Endometriosis-Pipeline by Repros Therapeutics Inc., H1 2016 41

Endometriosis-Pipeline by SK Chemicals Co., Ltd., H1 2016 42

Endometriosis-Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 43

Endometriosis-Pipeline by ValiRx Plc, H1 2016 44

Assessment by Monotherapy Products, H1 2016 45

Assessment by Combination Products, H1 2016 46

Number of Products by Stage and Target, H1 2016 48

Number of Products by Stage and Mechanism of Action, H1 2016 51

Number of Products by Stage and Route of Administration, H1 2016 53

Number of Products by Stage and Molecule Type, H1 2016 55

Endometriosis Therapeutics-Recent Pipeline Updates, H1 2016 105

Endometriosis-Dormant Projects, H1 2016 120

Endometriosis-Dormant Projects (Contd..1), H1 2016 121

Endometriosis-Discontinued Products, H1 2016 122

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AbbVie Inc. Addex Therapeutics Ltd APAvadis Biotechnologies Srl Astellas Pharma Inc. Bayer AG Dongkook Pharmaceutical Co., Ltd. ElexoPharm GmbH EndoCeutics, Inc. Euroscreen S.A. Evotec AG Forendo Pharma Limited GlaxoSmithKline Plc Kissei Pharmaceutical Co., Ltd. Lipicard Technologies Limited Nippon Shinyaku Co., Ltd. Orphagen Pharmaceuticals, Inc. Philogen S.p.A. Repros Therapeutics Inc. SK Chemicals Co., Ltd. Takeda Pharmaceutical Company Limited ValiRx Plc

Endometriosis Therapeutic Products under Development, Key Players in Endometriosis Therapeutics, Endometriosis Pipeline Overview, Endometriosis Pipeline, Endometriosis Pipeline Assessment

select a license
Single User License
USD 2000 INR 143840
Site License
USD 4000 INR 287680
Corporate User License
USD 6000 INR 431520

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com